Good
Mostly Aligned
Patient Risk:
Low
Summary
Most factual pharmacology, indication, dosing form/frequency, and common adverse reactions are supported by the provided ORGOVYX label excerpts. However, several claims are unsupported or not directly stated (notably the stated retail price, several mechanistic details, and the claim that LH decrease directly leads to significant sustained testosterone decrease).
Category Scores
Accurate Statements
Relugolix is marketed under the brand name Orgovyx.
Label description/brand context: ORGOVYX is the product name for relugolix (Section 11 DESCRIPTION; provided excerpts consistently refer to ORGOVYX/relugolix).
Orgovyx is used for the treatment of advanced prostate cancer.
INDICATIONS AND USAGE: “ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer.”
Relugolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist.
DESCRIPTION: “Relugolix is a nonpeptide GnRH receptor antagonist” and “film-coated tablets for oral administration.”
Relugolix binds to the GnRH receptor in the anterior pituitary gland.
Mechanism of action: “competitively binds to pituitary GnRH receptors” (Section 12.1).
Relugolix prevents GnRH from binding to its receptor.
Mechanism of action: “competitive binds to pituitary GnRH receptors” (Section 12.1).
Relugolix suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Mechanism of action (Section 12.1): “reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)”
Relugolix has been approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer.
INDICATIONS AND USAGE indicates the drug’s labeled indication for ORGOVYX (provided excerpts).
Relugolix is taken orally as a tablet.
DESCRIPTION: “ORGOVYX is provided as film-coated tablets for oral administration.”
Relugolix is typically taken once daily.
HERO dosing described: “followed by 120 mg taken orally once daily” (Sections 6.1 and 14).
Common side effects associated with Orgovyx include hot flashes.
ADVERSE REACTIONS: “hot flush (54%)” (Section 6.1).
Common side effects associated with Orgovyx include fatigue.
ADVERSE REACTIONS: “fatigue (26%)” (Section 6.1).
Common side effects associated with Orgovyx include decreased libido.
Clinically relevant adverse reactions <10%: “decreased libido” (Section 6.1).
Common side effects associated with Orgovyx include diarrhea.
ADVERSE REACTIONS: “diarrhea (12%)” (Section 6.1).
Common side effects associated with Orgovyx include constipation.
ADVERSE REACTIONS: “constipation (12%)” (Section 6.1).
Serious side effects of Orgovyx can include QT interval prolongation.
WARNINGS AND PRECAUTIONS 5.1: “may prolong the QT/QTc interval.” (Note: label uses risk statement; it is not framed as an adverse reaction event in the provided excerpt.)
Serious side effects of Orgovyx can include liver enzyme elevations.
ADVERSE REACTIONS: “ALT increased (27%)” and “AST increased (18%)” (Section 6.1) (though label excerpt does not label these as “serious.”)
Clinical trials (e.g., the HERO study) have demonstrated efficacy of relugolix in achieving and maintaining testosterone suppression in men with advanced prostate cancer.
CLINICAL STUDIES/Pharmacodynamics: HERO efficacy described via maintaining castrate testosterone levels through 48 weeks; testosterone suppression in Sections 12.2 and 14.
Relugolix leads to a rapid decrease in testosterone production by the testes.
Pharmacodynamics: “reduced LH, FSH and testosterone concentrations after oral administration…” and “56% had testosterone… by Day 4” (Section 12.2).
Unsupported Statements
The average retail price for a 30-day supply of Orgovyx is approximately $9,000.
No pricing information is present in the provided ORGOVYX label excerpts.
Relugolix blocks the GnRH receptor in the pituitary gland.
The label excerpt states competitive binding and reduced release of LH/FSH, but does not use wording equivalent to “blocks” in the provided text.
Relugolix rapidly reduces the production of luteinizing hormone (LH).
The label excerpt supports testosterone reduction rapidly (e.g., Day 4 castrate levels) but does not provide a specific time-to-LH suppression statement.
Reduction of LH from relugolix leads to a significant and sustained decrease in testosterone levels.
The label supports reduced LH/FSH and testosterone suppression, and supports sustained castrate testosterone through 48 weeks, but it does not explicitly link “LH reduction leads to testosterone decrease” as a causal chain in the provided excerpt.
Decreased testosterone levels are a key factor that fuels prostate cancer growth.
The provided label excerpts describe mechanism of action and testosterone suppression but do not state that reduced testosterone is a “key factor that fuels prostate cancer growth.”
Relugolix leads to a rapid decrease in testosterone production by the testes.
The label excerpt supports reductions in testosterone concentrations after dosing (and castrate levels by Day 4), but does not explicitly attribute testosterone reduction to “production by the testes.”
Relugolix prevents GnRH from binding to its receptor.
The label excerpt describes competitive binding to pituitary GnRH receptors, but does not explicitly state “prevents GnRH from binding.”
Serious side effects of Orgovyx can include liver enzyme elevations.
The label excerpts list ALT/AST increases as common adverse reactions (laboratory abnormalities), but “serious side effects” is not explicitly applied to liver enzyme elevations in the provided excerpt.
Contradictions
Important Omissions
Dose initiation includes a loading dose (360 mg on Day 1) followed by 120 mg once daily; the claim “typically taken once daily” omits the loading-dose step.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims largely match labeled indication, oral tablet administration, once-daily maintenance dosing, and commonly reported adverse reactions. Main safety relevance stems from potential overstatement/unsupported mechanistic or “serious side effect” framing, and omission of the loading dose; however, no direct contradictions to the provided label excerpts were identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements are unsupported or imprecise relative to the provided label excerpts (pricing; certain mechanistic assertions/timing; “serious” framing; causal phrasing).
Suggested Improvement
Restrict mechanistic statements to the label wording (competitive binding; reduction of LH/FSH; testosterone suppression) and avoid unsupported causal chains or speculative timing. Remove or verify non-label claims such as retail pricing. Use label-consistent language for adverse reactions (e.g., ALT/AST increased are listed as common reactions/lab abnormalities, not explicitly “serious”). Include the Day 1 loading dose when describing dosing.